Pfizer的70B美元美国交易面临对所指称的优惠待遇和缺乏透明度的强烈反弹。 Pfizer's $70B U.S. deal faces backlash over alleged preferential treatment and lack of transparency.

Pfizer与美国政府之间一项700亿美元的协议受到仔细审查, 批评者认为这是向公司提供优惠待遇并保护其免于问责的回报, 尽管关于协议条件的官方细节仍然有限。 A $70 billion agreement between Pfizer and the U.S. government has drawn scrutiny, with critics labeling it a payoff that offers the company preferential treatment and shields it from accountability, though official details on the deal's terms remain limited.